Nutriband CEO Highlights Fentanyl Crisis and AVERSA Tech on Jack Neel Podcast
Event summary
- Nutriband CEO Gareth Sheridan discussed the US fentanyl crisis and the company's AVERSA technology on the Jack Neel Podcast on April 22, 2026.
- AVERSA is an abuse-deterrent transdermal technology designed to prevent misuse of drugs like fentanyl.
- The technology is covered by patents in multiple countries, including the US, Europe, and China.
- Nutriband's lead product is an abuse-deterrent fentanyl patch incorporating AVERSA technology.
The big picture
Nutriband's focus on abuse-deterrent technology comes at a critical time as the US grapples with the fentanyl crisis. The company's AVERSA technology aims to address the safety concerns associated with transdermal drugs, positioning Nutriband as a potential leader in the development of safer pain management solutions. The strategic significance lies in the broader industry shift towards abuse-deterrent formulations, driven by regulatory and public health pressures.
What we're watching
- Regulatory Approval
- The pace at which Nutriband secures FDA approval for its abuse-deterrent fentanyl patch will determine its market entry timeline.
- Technology Adoption
- Whether healthcare providers and patients will adopt AVERSA technology as a safer alternative to traditional fentanyl patches.
- Market Competition
- How Nutriband's AVERSA technology will compete with existing and emerging abuse-deterrent solutions in the pharmaceutical market.
Related topics